← Back to Search

MEK Inhibitor

Binimetinib + Hydroxychloroquine for Non-Small Cell Lung Cancer

Phase 2

Waitlist Available

Led By Joshua Bauml, MD

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will study whether using hydroxychloroquine (HCQ) with binimetinib can effectively treat cancer in patients with a KRAS mutation.

Eligible Conditions

Non-Small Cell Lung Cancer
Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Patients with Adverse Events as assessed by CTCAE v5.0

Objective Response Rate

Secondary outcome measures

Number of changes in ctDNA KRAS allelic frequency (blood)

Overall survival (OS)

progression-free survival (PFS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Binimetinib and HydroxychloroquineExperimental Treatment2 Interventions

Hydroxychloroquine (HCQ)in combination with Binimetinib (B). The starting dose for HCQ will be 400mg. Tablets of HCQ are available in 200 mg strength. HCQ will be administered in divided doses (every 12 hours) with or without food. The starting dose of B is 45mg. B will be administered in divided doses (every 12 hours) with or without food

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Hydroxychloroquine Pill

2020

N/A

~200

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,053 Total Patients Enrolled

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,653 Total Patients Enrolled

PfizerIndustry Sponsor

4,570 Previous Clinical Trials

10,910,467 Total Patients Enrolled

Media Library

Binimetinib (MEK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04735068 — Phase 2

Non-Small Cell Lung Cancer Research Study Groups: Binimetinib and Hydroxychloroquine

Non-Small Cell Lung Cancer Clinical Trial 2023: Binimetinib Highlights & Side Effects. Trial Name: NCT04735068 — Phase 2

Binimetinib (MEK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04735068 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor recruiting participants right now?

"Clinicaltrials.gov reports that this trial is actively enrolling patients, with the original posting occurring on April 9th 2021 and most recent alterations made to it on September 30th 2022."

Answered by AI

Could you enumerate the previous experiments with Hydroxychloroquine Pill?

"Presently, 121 clinical trials are underway for the Hydroxychloroquine Pill with 10 Phase 3 studies. Cambridge is a major site of research; however, 3857 other locations worldwide have also been conducting experiments on this medication."

Answered by AI

How might Hydroxychloroquine Pill impact a person’s safety?

"Our team at Power assigned Hydroxychloroquine Pill a score of 2, as there is evidence to suggest its safety but no data that conclusively proves its efficacy."

Answered by AI

What is the participant capacity for this clinical trial?

"Correct. Clinicaltrials.gov contains evidence of this trial's ongoing recruitment, which began on April 9th 2021 and was last modified on September 30th 2022. The study is looking to enroll 29 individuals from a single medical centre."

Answered by AI

In what health conditions is Hydroxychloroquine Pill regularly utilized?

"Hydroxychloroquine Pill is generally prescribed to treat metastatic melanoma, but can also be beneficial in managing sjögren's syndrome, malaria and unresectable forms of the disease."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

2021. "Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04735068.